Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoreCyte
- Development stage
- Unknown
- Lead developer
- Predictive Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intramuscular, Soft Tissue Injection
01
Overview
CoreCyte is a human cell, tissue, and cellular and tissue-based product (HCT/P) derived from the umbilical cord, developed by Predictive Biotech. It is processed as a minimally manipulated tissue allograft containing components from the umbilical cord, specifically Wharton's Jelly, which is rich in mesenchymal stem cells (MSCs), cytokines, growth factors, and hyaluronic acid. CoreCyte is primarily utilized in regenerative medicine and orthopedic clinical settings to provide structural support, cushioning, and lubrication to damaged or inadequate connective tissues, such as those in joints. While it is marketed under Section 361 of the Public Health Service Act as a structural tissue product, the FDA has issued warnings regarding the marketing of such umbilical cord-derived products as unapproved biologics for systemic or non-homologous therapeutic uses.
- Brand names
- CoreCyte
- Other names
- umbilical cord tissue allograftWharton's Jelly allograft
Beyond the preview
Go deeper on CoreCyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoreCyte.